- Home
- MGLD vs MURA Comparison
MGLD vs MURA Comparison
Compare MGLD & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MGLD | MURA |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 36.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MGLD | MURA |
|---|---|---|
| Price | $0.93 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 14.7K | ★ 224.8K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,207,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.95 |
| 52 Week High | $2.10 | $4.74 |
Technical Indicators
Market Signals| Indicator | MGLD | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 40.40 |
| Support Level | $0.91 | $2.06 |
| Resistance Level | $1.09 | $2.10 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.00 | 25.00 |
Price Performance
Historical ComparisonAbout MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.